Print Magazine
Brussels Morning Newspaper
Thursday, June 8, 2023
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home EU Institutions

EU countries kickstart vaccination campaigns amid criticism of COVID-19 vaccines transparency

Marta Pacheco by Marta Pacheco
16 September 2022
in EU Institutions
EU countries kickstart vaccination campaigns amid criticism of COVID-19 vaccines transparency
Share on FacebookShare on Twitter

Belgium, (Brussels Morning) Across the EU, member states are rolling out vaccination campaigns, aiming at encouraging those who have already been vaccinated with at least a first shot. Belgium kicked off its autumn vaccination campaign encouraging citizens to get a Covid-19 booster. The rollout started with Flanders setting up 80 vaccination center and Wallonia another 22. 

Following the recommendation from the World Health Organisation (WHO), most EU countries are now ready to provide booster shots. Portugal, Italy, Germany, France and many others are now administrating COVID-19 vaccines, some of them, together with the flu shot.

While most EU countries have lifted off restrictions and the pandemic has seemingly calmed down, national governments are still engaged on vaccination campaigns, targeted to the elderly and those more at risk of progressing to severe disease because of certain risk factors.

“Vaccinating everyone who is eligible with the recommended number of primary doses and the first booster dose must remain a priority across the European Region. But a second booster shot should also be provided to the immunocompromised, and be considered for other vulnerable people, to reduce the risk of severe disease and the resulting burden on health systems,” said Hans Kluge, WHO’s Europe Director.

Dubious procurement

The national vaccination rollout comes days after an official meeting where MEPs from the special committee on COVID-19 (COVI) received four pharmaceutical companies that worked on developing vaccines and therapeutics during the pandemic — Gilead Sciences, Sanofi, AstraZeneca and Moderna.

During the meeting, Romanian MEP Cristian Terhes launched key questions to Moderna’s CEO Stéphane Bancel about the decoding of the full DNA sequence of the Sar-Cov-2 virus, how the pharmaceutical giant dealt with testing the jabs and the lack of transparency of procurement contracts.

“In the case of Moderna, for example, you provided data showing that you tested these vaccines since 2017, 2018 and 2019. How were you able to test these vaccines back then when we found out about this virus in December 2019?” asked Terhes, referring to a documented answer from the European Medicines Agency (EMA) showing the kind of tests that have been conducted by the pharmaceuticals. 

Bancel said he was “not aware” of the EMA document and explained that the vaccine testing conducted by Moderna is part of the company’s general clinical trials on flu, RSV and other pandemic flu strains.

Terhes maintained his critical stance towards Moderna while showing the contracts between the Commission and Moderna, featuring pages almost entirely blacked out and urging Moderna to fully publish both contracts signed with the European Commission and with EU countries.

“Do you think this is far to all of us? To talk about these vaccines, to talk about boosters and medical products, when we don’t know the clauses of these contracts?” Terhes went on, claiming that the interests of the European citizens should not be dismissed over those of the Union.

“Freedom of Information Act (FOIA) requests for more information on COVID-19 contracts have been submitted by citizens and civil society groups in some countries. However, many requests have been denied,” said Transparency International.

New adapted vaccines

Recently, EMA authorized two Omicron adapted bivalent COVID-19 vaccines — Comirnaty Original/Omicron BA.1 and Spikevax Bivalent Original/Omicron BA.1. 

MEP Terhes noted during the COVI meeting that these bivalent boosters were requested and approved by the US without trials on humans. Yet, Moderna’s Bencel reacted saying that, in Europe, the new vaccines were tested in humans, confirming that in the US, the clinical studies were skipped.

EMA’s Executive Director Emer Cooke said the authorisation of the first two adapted vaccines was an important step in the ongoing fight against the pandemic. “We have a virus that evolves quickly and unpredictably. It is important for the EU to have a broad range of vaccines that are updated with respect to their composition, so Member States have more options to meet their needs when designing their vaccination strategies,” said Cooke.

Corruption

Trying to dig further, after a series of investigations on COVID-19 vaccines, last year Investigate Europe revealed that deals for doses happen behind closed doors between the EU and pharmaceutical companies. 

The investigative media group further unveiled that new variants, international competition and darkness around manufacturing costs have allowed Pfizer/Biontech and Moderna to increase the bill for European taxpayers.

Transparency International has also been vocal on the lack of transparency of COVID-19 vaccines procurement: “Corruption in public procurement remains a risk as countries develop contracts with pharmaceutical companies to procure vaccines. Contracts and pricing agreements between governments and pharmaceutical companies often remain confidential, despite the drugs being paid for with taxpayer money,” Transparency International stated last year.

On 10 October 2022, COVI will organise a second debate with the pharmaceutical industry including Pfizer, GSK, CureVac, Novavax, Hipra and Valneva.

Tags: Biweekly MartaBrussels LatestEuropean UnionMain-Slider
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Belgium News
  • Brussels
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • Health & Fitness
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • Brussels Bubble
    • Parliament
    • Commission
    • Council
  • Wider Europe
    • Member States
  • World
  • Business & Society
  • Europe With Transparency
  • Culture & Society
  • Policy Talks
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • Ambassador’s Corner
    • The American Angle
    • Southeast Europe
  • Print Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT